Who are Novartis's key investors?

Key investors in Novartis include Bill & Melinda Gates Foundation.

How many employees does Novartis have?

As of Sat, 25 Apr 2026, Novartis has approximately 10,001+ employees employees.

How much website traffic does Novartis receive?

Novartis receives about 1.2M monthly website visits in the latest Datakart source snapshot. This helps benchmark market attention, demand generation, and digital reach.

Is Novartis currently hiring?

Novartis has 1.1K open roles in the latest source snapshot. Open job volume can indicate team expansion, budget movement, and active buying needs by department.

What technologies does Novartis use?

Novartis's detected technology footprint includes Microsoft 365, Icontrol, Brocade, Aos, Sap Ariba, Samsung. The full profile lists additional verified technologies when available.

Company profile

Pharmaceutical Manufacturing

Novartis - Company Intelligence Profile

Industry: Pharmaceutical Manufacturing | Founded: not publicly disclosed | HQ: Switzerland

Novartis is an innovative medicines company. Every day, working to reimagine medicine to improve and extend people’s lives so that patients, healthcare professionals and societies are empowered in the face of serious disease. Our medicines reach more than 250 million people worldwide.

Datakart tracks firmographic, hiring, traffic, technology, funding, review, and leadership signals for Novartis to help teams evaluate the account with useful business context.

Public Company

Novartis

novartis.com

Employees

84.1K

Monthly visits

1.2M

Open roles

1.1K

Search volume

40.5K

View intelligence Start free trial

Company Snapshot

Find out more at https://www.novartis.com

See our community guidelines: https://go.novartis.social/3Nboxki

N/A

Founded

84.1K

Employee count

1.2M

Monthly website visits

1.1K

Open roles

Company Snapshot Details

Legal name: Novartis

Headquarters: Basel, Baselstadt, Switzerland

Industry: Pharmaceutical Manufacturing

Sub-sector: Pharmaceutical Manufacturing

Website: https://www.novartis.com

YoY headcount growth: not publicly disclosed

Company stage: Public Company

Last updated: Sat, 25 Apr 2026

Company intelligence

Business signals that help qualify Novartis

This profile combines firmographic, traffic, hiring, employee, review, compensation, technology, funding, leadership, and product availability signals so visitors can answer practical business questions without hunting across multiple data sources.

Source snapshot

Last refreshed 2026-04-25 | 41K search volume | Domain novartis.com

Annual revenue

$54.1B

Reported annual revenue from the source dataset when available.

Quarterly revenue

$14.4B

Standalone quarterly revenue field from the source dataset.

Monthly visits

1.2M

Latest monthly visits value available from the source dataset.

Global web rank

#42,290

Lower rank values indicate stronger web visibility in the source dataset.

Employees

84.1K

Latest employees value available from the source dataset.

-30 monthly (-2.6%)

Hiring demand

1.1K

Open roles reveal which teams may be expanding and where vendor demand can emerge. For Novartis, this signal is based on the latest available source snapshot.

+280 monthly (+0.3%)

Headcount momentum

84.1K

Recent employee count movement helps qualify growth, contraction, and operational scale. For Novartis, this signal is based on the latest available source snapshot.

+34.9K monthly (+0.8%)

Audience growth

4.6M

LinkedIn follower movement is a useful proxy for employer brand, market attention, and hiring reach. For Novartis, this signal is based on the latest available source snapshot.

+206.2K monthly (+21.7%)

Web demand

1.2M

Website traffic movement helps benchmark customer interest and go-to-market momentum. For Novartis, this signal is based on the latest available source snapshot.

Identity atlas

Novartis identity, aliases, ownership, and taxonomy

This section makes the entity easier to verify: canonical domains, alternate names, descriptions, ownership flags, parent or acquirer context, industry codes, and source-level social reach are grouped together.

Company descriptions

All available company description fields from the source dataset.

Company descriptiondescription

Enriched descriptionDescription Enriched

Novartis is a pharmaceutical company that works together to reimagine medicine to improve and extend people’s lives.

Metadata descriptionDescription Metadata Raw

Working together, we can reimagine medicine to improve and extend people’s lives.

LinkedIn followers

4.6M

Latest linkedin followers value available from the source dataset.

Owler followers

28.8K

Latest owler followers value available from the source dataset.

Technologies detected

978

Latest technologies detected value available from the source dataset.

Ownership and corporate structure

Ownership status, parent company, acquisition status, and public/B2B flags.

Operating status

Active

Independent Company

Company type

Public Company

type

Ownership status

Public

Ownership Status

Public company

Is Public

Aliases and domain variants

Company name aliases, website aliases, and canonical domain signals.

Company alias

novartis

Company Name Alias

Company alias

novartis ag

Company Name Alias

Website alias

https://www.novartis.com

Website Alias

Website alias

https://www.novartis.com/

Website Alias

Canonical website

https://www.novartis.com

website

Website domain

novartis.com

Website Domain

Unique website

Yes

Unique Website

Unique domain

Yes

Unique Domain

Expired domain

Expired Domain

LinkedIn shorthand

novartis

Canonical LinkedIn Shorthand Name

Source ID

1406

Source ID

UUID

73Y63EWNAW1P0FAA6CDAWW2AB1

uuid

Industry classification codes

SIC, NAICS, industry, and keyword classification signals.

Industry

Pharmaceutical Manufacturing

industry

Categories and keywords

['pharmaceuticals', 'cardiovascular', 'immunology', 'neuroscience', 'solid tumors', 'hematology', 'chemistry', 'xrna', 'radioligand', 'gene and cell therapy', 'improve', 'medicine', 'extend', 'pharmaceutical', 'reimagine', 'health', 'biotech', 'clinical-research', 'drug-development', 'oncology', 'pharma']

Categories And Keywords

Social follower counts

Follower counts available across LinkedIn, Twitter, and Owler.

LinkedIn followers

4.6M

Followers Count LinkedIn

Owler followers

28.8K

Followers Count Owler

Company locations

Known company locations and office addresses.

Primary location

Novartis Campus; Basel, Baselstadt 4002, CH

Office location

Lima, PE

Office location

Baku, AZ

Office location

Caracas, VE

Office location

Moscow, RU

Office location

Dakar, SN

Office location

Brussels, BE

Office location

Doha, QA

Social profiles

Official and source-linked social profiles.

Website

https://www.novartis.com

https://www.linkedin.com/company/novartis

Facebook

https://www.facebook.com/novartis

Twitter / X

https://www.twitter.com/novartis

Instagram

https://www.instagram.com/novartis

YouTube

https://www.youtube.com/user/novartis

Company contact points

Public company-level contact points available in the source dataset.

Phone

41-61-324-1111

Financial intelligence

Novartis revenue, funding, IPO, and acquisition history

Financial signals are grouped as an analyst-style view: revenue sources, income statement rows, funding rounds, acquisition activity, IPO fields, stock listing context, and ownership structure.

Annual revenue

$54.1B

Reported annual revenue from the source dataset when available.

Quarterly revenue

$14.4B

Standalone quarterly revenue field from the source dataset.

Total disclosed funding

$8.5B

Sum of disclosed funding round amounts available in the source dataset.

Funding rounds

Number of funding rounds captured in the source dataset.

Acquisitions captured

110

Number of acquisition records captured across the available source columns.

Revenue signals

Annual, quarterly, and range-based revenue signals available in the source dataset.

Source 5

$54.1B

Annual revenue

Source 1$56.7B

Standalone quarterly revenue$14.4B

IPO and stock listing

IPO date, share price, exchange tickers, and public market identifiers.

Stock ticker

NVS

NYSE

Stock tickerNOVN.SW

Latest closing priceCHF 95.74

Ownership and corporate structure

Ownership status, parent company, acquisition status, and public/B2B flags.

Operating status

Active

Independent Company

Company type

Public Company

type

Ownership status

Public

Ownership Status

Public company

Is Public

Income statement rows

Income statement rows with revenue and profitability metrics where available.

FY, 2025

Fiscal Year

Primary value

Revenue: $56.7B

Additional metrics

Gross profit: $49.8B; EBITDA: $23B; EBIT: $17.6B; Net income: $14B; Operating expense: $26.8B; Gross margin: 87.8%; EBITDA margin: 40.5%

Q3, 2025

Primary value

Revenue: $14.4B

Additional metrics

Gross profit: $12.5B; EBITDA: $5.9B; EBIT: $4.5B; Net income: $3.9B; Operating expense: $6.6B; Gross margin: 86.7%; EBITDA margin: 40.8%

Q2, 2025

Primary value

Revenue: $15.2B

Additional metrics

Gross profit: $13.3B; EBITDA: $6.1B; EBIT: $4.9B; Net income: $4B; Operating expense: $7.2B; Gross margin: 87.5%; EBITDA margin: 40.2%

Q1, 2025

Primary value

Revenue: $13.2B

Additional metrics

Gross profit: $11.8B; EBITDA: $5.8B; EBIT: $4.7B; Net income: $3.6B; Operating expense: $6B; Gross margin: 89.0%; EBITDA margin: 43.9%

FY, 2024

Fiscal Year

Primary value

Revenue: $51.7B

Additional metrics

Gross profit: $45.2B; EBITDA: $19.7B; EBIT: $14.5B; Net income: $11.9B; Operating expense: $25.5B; Gross margin: 87.5%; EBITDA margin: 38.0%

Q3, 2024

Primary value

Revenue: $13.2B

Additional metrics

Gross profit: $12.3B; EBITDA: $5.6B; EBIT: $3.6B; Net income: $3.2B; Operating expense: $6.7B; Gross margin: 93.1%; EBITDA margin: 42.4%

Q2, 2024

Primary value

Revenue: $13.2B

Additional metrics

Gross profit: $11.1B; EBITDA: $5.2B; EBIT: $4B; Net income: $3.2B; Operating expense: $6B; Gross margin: 84.6%; EBITDA margin: 39.3%

Q1, 2024

Primary value

Revenue: $11.8B

Additional metrics

Gross profit: $10.6B; EBITDA: $4.7B; EBIT: $3.3B; Net income: $2.7B; Operating expense: $5.9B; Gross margin: 89.5%; EBITDA margin: 39.4%

FY, 2023

Fiscal Year

Primary value

Revenue: $54.1B

Additional metrics

Gross profit: $47.7B; EBITDA: $18.3B; EBIT: $10B; Net income: $9B; Operating expense: $29.4B; Gross margin: 88.2%; EBITDA margin: 33.8%

Q3, 2023

Primary value

Revenue: $7.7B

Additional metrics

Gross profit: $11.6B; EBITDA: $6.3B; EBIT: $1.4B; Net income: $1.3B; Operating expense: $5.4B; Gross margin: 1.5%; EBITDA margin: 81.0%

Q2, 2023

Primary value

Revenue: $14.2B

Additional metrics

Gross profit: $9.6B; EBITDA: $2.7B; EBIT: $2.9B; Net income: $2.3B; Operating expense: $6.8B; Gross margin: 67.4%; EBITDA margin: 19.4%

Q1, 2023

Primary value

Revenue: $13B

Additional metrics

Gross profit: $12.2B; EBITDA: $4.9B; EBIT: $2.9B; Net income: $2.3B; Operating expense: $7.4B; Gross margin: 94.5%; EBITDA margin: 37.5%

Period	Primary value	Additional metrics
FY, 2025 Fiscal Year	Revenue: $56.7B	Gross profit: $49.8B; EBITDA: $23B; EBIT: $17.6B; Net income: $14B; Operating expense: $26.8B; Gross margin: 87.8%; EBITDA margin: 40.5%
Q3, 2025 Q3	Revenue: $14.4B	Gross profit: $12.5B; EBITDA: $5.9B; EBIT: $4.5B; Net income: $3.9B; Operating expense: $6.6B; Gross margin: 86.7%; EBITDA margin: 40.8%
Q2, 2025 Q2	Revenue: $15.2B	Gross profit: $13.3B; EBITDA: $6.1B; EBIT: $4.9B; Net income: $4B; Operating expense: $7.2B; Gross margin: 87.5%; EBITDA margin: 40.2%
Q1, 2025 Q1	Revenue: $13.2B	Gross profit: $11.8B; EBITDA: $5.8B; EBIT: $4.7B; Net income: $3.6B; Operating expense: $6B; Gross margin: 89.0%; EBITDA margin: 43.9%
FY, 2024 Fiscal Year	Revenue: $51.7B	Gross profit: $45.2B; EBITDA: $19.7B; EBIT: $14.5B; Net income: $11.9B; Operating expense: $25.5B; Gross margin: 87.5%; EBITDA margin: 38.0%
Q3, 2024 Q3	Revenue: $13.2B	Gross profit: $12.3B; EBITDA: $5.6B; EBIT: $3.6B; Net income: $3.2B; Operating expense: $6.7B; Gross margin: 93.1%; EBITDA margin: 42.4%
Q2, 2024 Q2	Revenue: $13.2B	Gross profit: $11.1B; EBITDA: $5.2B; EBIT: $4B; Net income: $3.2B; Operating expense: $6B; Gross margin: 84.6%; EBITDA margin: 39.3%
Q1, 2024 Q1	Revenue: $11.8B	Gross profit: $10.6B; EBITDA: $4.7B; EBIT: $3.3B; Net income: $2.7B; Operating expense: $5.9B; Gross margin: 89.5%; EBITDA margin: 39.4%
FY, 2023 Fiscal Year	Revenue: $54.1B	Gross profit: $47.7B; EBITDA: $18.3B; EBIT: $10B; Net income: $9B; Operating expense: $29.4B; Gross margin: 88.2%; EBITDA margin: 33.8%
Q3, 2023 Q3	Revenue: $7.7B	Gross profit: $11.6B; EBITDA: $6.3B; EBIT: $1.4B; Net income: $1.3B; Operating expense: $5.4B; Gross margin: 1.5%; EBITDA margin: 81.0%
Q2, 2023 Q2	Revenue: $14.2B	Gross profit: $9.6B; EBITDA: $2.7B; EBIT: $2.9B; Net income: $2.3B; Operating expense: $6.8B; Gross margin: 67.4%; EBITDA margin: 19.4%
Q1, 2023 Q1	Revenue: $13B	Gross profit: $12.2B; EBITDA: $4.9B; EBIT: $2.9B; Net income: $2.3B; Operating expense: $7.4B; Gross margin: 94.5%; EBITDA margin: 37.5%

Funding rounds

Funding history and recent round context.

Post-IPO Debt

$6B

2025-11-01

Post-IPO Debt

$2.5B

2024-06-19

Grant

$6.5M

2018-02-14 | Bill & Melinda Gates Foundation

Post-IPO Equity

1995-04-01

Acquisitions and corporate activity

Acquisitions and corporate activity captured in the source dataset.

Excellergy Inc.

$2B

2026-03-01 | Acquisition List Source 5

Avidity Biosciences, Inc.

$12B

2025-10-01 | Acquisition List Source 5

Tourmaline Bio, Inc.

$1.4B

2025-09-01 | Acquisition List Source 5

Regulus Therapeutics

$1.7B

2025-04-30 | Acquisition List Source 1

Regulus Therapeutics, Inc.

$1.7B

2025-04-01 | Acquisition List Source 5

Anthos Therapeutics

$925M

2025-02-10 | Acquisition List Source 1

Anthos Therapeutics, Inc.

$925M

2025-02-01 | Acquisition List Source 5

Kate Therapeutics

$1.1B

2024-11-21 | Acquisition List Source 1

Kate Therapeutics, Inc.

$1.1B

2024-11-01 | Acquisition List Source 5

Calypso Biotech

$250M

2024-08-01 | Acquisition List Source 1

Mariana Oncology, Inc.

$1B

2024-05-01 | Acquisition List Source 5

IFM Due, Inc

$90M

2024-03-01 | Acquisition List Source 5

MorphoSys AG

$2.9B

2024-02-01 | Acquisition List Source 5

SanReno Therapeutics

Acquisition

2024-01-05 | Acquisition List Source 1

SanReno Therapeutics

Acquisition

2024-01-01 | Acquisition List Source 5

DTx Pharma

$1B

2023-07-17 | Acquisition List Source 1

Chinook Therapeutics

$3.5B

2023-06-12 | Acquisition List Source 1

Gyroscope Therapeutics

$1.5B

2021-12-22 | Acquisition List Source 1

Arctos Medical

Acquisition

2021-09-17 | Acquisition List Source 1

Cellerys

Acquisition

2021-06-01 | Acquisition List Source 1

Cadent Therapeutics

$770M

2020-12-17 | Acquisition List Source 1

Vedere Bio

$280M

2020-10-29 | Acquisition List Source 1

Vedere Bio ll

$280M

2020-10-29 | Acquisition List Source 1

Amblyotech

Acquisition

2020-04-21 | Acquisition List Source 1

The Medicines Company

$9.7B

2019-11-25 | Acquisition List Source 1

Xiidra

$1.9B

2019-05-09 | Acquisition List Source 1

Mariana Oncology

$1.8B

2019-05-02 | Acquisition List Source 1

Novartis Inflammasome Research

$1.6B

2019-04-02 | Acquisition List Source 1

CellforCure

Acquisition

2018-12-21 | Acquisition List Source 1

Endocyte

Acquisition

2018-10-18 | Acquisition List Source 1

Novartis Gene Therapies

$8.7B

2018-04-09 | Acquisition List Source 1

Advanced Accelerator Applications

$3.9B

2017-10-30 | Acquisition List Source 1

Encore Vision

Acquisition

2016-12-20 | Acquisition List Source 1

Ziarco

Acquisition

2016-12-16 | Acquisition List Source 1

Selexys Pharmaceuticals Corporation

$665M

2016-11-21 | Acquisition List Source 1

Admune Therapeutics

Acquisition

2015-10-21 | Acquisition List Source 1

Spinifex Pharmaceuticals

$200M

2015-06-29 | Acquisition List Source 1

CoStim Pharmaceuticals

Acquisition

2014-02-18 | Acquisition List Source 1

Fougera Pharmaceuticals

$1.5B

2012-05-02 | Acquisition List Source 1

Alcon

$12.9B

2010-12-15 | Acquisition List Source 1

Corthera

$120M

2009-12-23 | Acquisition List Source 1

Protez Pharmaceuticals

$400M

2008-06-01 | Acquisition List Source 1

Chiron Corporation

$5.1B

2005-11-01 | Acquisition List Source 1

Hexal

$8.3B

2005-02-22 | Acquisition List Source 1

Sandoz Canada Inc.

Acquisition

Acquisition List Source 1

Novartis Argentina S.A.

Acquisition

Acquisition List Source 1

Novartis Pharma S.A.S.

Acquisition

Acquisition List Source 1

Sandoz Pty Ltd

Acquisition

Acquisition List Source 1

Novartis de Venezuela, S.A.

Acquisition

Acquisition List Source 1

Novartis Norge AS

Acquisition

Acquisition List Source 1

Novartis Services, Inc.

Acquisition

Acquisition List Source 1

Novartis Pharmaceuticals Corporation

Acquisition

Acquisition List Source 1

Novartis Pharma AG

Acquisition

Acquisition List Source 1

Coalesce Product Development Limited

Acquisition

Acquisition List Source 1

Cadent Therapeutics, Cambridge

Acquisition

Acquisition List Source 1

Sandoz Manufacturing Inc.

Acquisition

Acquisition List Source 1

Manufacturing Pte Ltd,

Acquisition

Acquisition List Source 1

Eon Labs, Inc.

Acquisition

Acquisition List Source 1

Ciba-Geigy Japan Limited

Acquisition

Acquisition List Source 1

Sandoz GmbH

Acquisition

Acquisition List Source 1

Novartis (Taiwan) Co., Ltd

Acquisition

Acquisition List Source 1

Novartis Healthcare Philippines, Inc.

Acquisition

Acquisition List Source 1

Neutec Pharma Limited

Acquisition

Acquisition List Source 1

Lek Pharmaceuticals d.d.

Acquisition

Acquisition List Source 1

1 A Pharma GmbH

Acquisition

Acquisition List Source 1

Novartis Pharma (Pakistan) Limited

Acquisition

Acquisition List Source 1

Research, Inc

Acquisition

Acquisition List Source 1

Salutas Pharma GmbH

Acquisition

Acquisition List Source 1

Novartis Securities Investment Ltd

Acquisition

Acquisition List Source 1

Novartis (Singapore) Pte Ltd

Acquisition

Acquisition List Source 1

Fougera Pharmaceuticals Inc

Acquisition

Acquisition List Source 1

CELLforCURE

Acquisition

Acquisition List Source 1

Beijing Novartis Pharma Co., Ltd.

Acquisition

Acquisition List Source 1

Sandoz K.K.

Acquisition

Acquisition List Source 1

Ilaçlari Sanayi ve Ticaret A.S

Acquisition

Acquisition List Source 1

Novartis Sverige AB

Acquisition

Acquisition List Source 1

Novartis Pharma GmbH

Acquisition

Acquisition List Source 1

Novartis Netherlands B.V.

Acquisition

Acquisition List Source 1

Novartis Business Services GmbH

Acquisition

Acquisition List Source 1

Novartis Overseas Investments AG

Acquisition

Acquisition List Source 1

Kedalion Therapeutics, Inc.

Acquisition

Acquisition List Source 1

BioMedical Research Co., Ltd.

Acquisition

Acquisition List Source 1

Australia Pty Ltd

Acquisition

Acquisition List Source 1

Co., Ltd

Acquisition

Acquisition List Source 1

Japat AG

Acquisition

Acquisition List Source 1

Novartis Farma S.p.A.

Acquisition

Acquisition List Source 1

Novartis Pharmaceuticals UK Limited

Acquisition

Acquisition List Source 1

Novartis Vietnam Company Limited

Acquisition

Acquisition List Source 1

Sandoz NV

Acquisition

Acquisition List Source 1

Sandoz Hungary Limited Liability Company

Acquisition

Acquisition List Source 1

Novartis Saudi Ltd.

Acquisition

Acquisition List Source 1

Novartis Pharmaceuticals Canada Inc.

Acquisition

Acquisition List Source 1

Iberica, S.L.U.

Acquisition

Acquisition List Source 1

Novartis Pharma Schweiz AG

Acquisition

Acquisition List Source 1

Navigate BioPharma Services, Inc

Acquisition

Acquisition List Source 1

Alcon – Couvreur NV

Acquisition

Acquisition List Source 1

Sandoz A/S

Acquisition

Acquisition List Source 1

Oriel Therapeutics, Inc.

Acquisition

Acquisition List Source 1

Sandoz Philippines Corporation

Acquisition

Acquisition List Source 1

Novartis Korea Ltd.

Acquisition

Acquisition List Source 1

Novartis Optogenetics Research, Inc.

Acquisition

Acquisition List Source 1

Sandoz Polska Sp. z o.o.,

Acquisition

Acquisition List Source 1

Novartis Bioventures AG

Acquisition

Acquisition List Source 1

Sandoz Limited

Acquisition

Acquisition List Source 1

HEXAL AG

Acquisition

Acquisition List Source 1

Novartis Israel Ltd

Acquisition

Acquisition List Source 1

Novartis Capital Corporation

Acquisition

Acquisition List Source 1

Novartis Investments S.à r.l.

Acquisition

Acquisition List Source 1

Novartis Poland Sp. z o.o.

Acquisition

Acquisition List Source 1

Novartis Corporation Sdn. Bhd.

Acquisition

Acquisition List Source 1

Audience analytics

Web visibility, demand, and topics

Use these signals to understand discoverability, demand quality, search interest, and audience fit.

Monthly visits

1.2M

Latest monthly visits value available from the source dataset.

Global web rank

#42,290

Lower rank values indicate stronger web visibility in the source dataset.

Bounce rate

49.0%

Latest bounce rate value available from the source dataset.

Pages per visit

3.55

Latest pages per visit value available from the source dataset.

Average visit duration

1m 29s

Latest average visit duration value available from the source dataset.

Estimated monthly page views

4.1M

Derived estimate calculated as monthly visits multiplied by pages per visit.

Website visits

Website visits trend from the latest source snapshots.

LinkedIn followers

LinkedIn followers trend from the latest source snapshots.

Website visits by country

United States27.93

Japan11.06

India8.77

Switzerland4.7

Turkey3.7

Employees, hiring, attrition, and compensation

This section groups org scale, hiring motion, employee movement, department mix, and salary benchmarks so teams can qualify operating momentum and budget signals.

Employees

84.1K

Latest employees value available from the source dataset.

Inferred employees

47.9K

Latest inferred employees value available from the source dataset.

Open roles

1.1K

Latest open roles value available from the source dataset.

Departures

Latest departures value available from the source dataset.

Employee attrition rate

0.0%

Latest employee attrition rate value available from the source dataset.

Hiring intensity

13.6 roles / 1K employees

Derived signal showing open roles normalized by employee count.

Employee headcount

Employee headcount trend from the latest source snapshots.

Inferred employees

Inferred employees trend from the latest source snapshots.

Open job postings

Open job postings trend from the latest source snapshots.

Employee attrition rate

Employee attrition rate trend from the latest source snapshots.

Employee count by department

Other Department7.6K

Research6.9K

Medical6.6K

Operations5.2K

Sales4.4K

Project Management3.1K

Technical2.7K

Employee count by seniority

Specialist15.4K

Manager9.3K

Other Management8.7K

Senior7K

Director5.4K

Head3.2K

Partner474

Employee count by region

Northern America11.5K

Western Europe10.4K

Southern Asia7.9K

Southern Europe4.1K

Latin America2.8K

Eastern Europe2.5K

Eastern Asia2.3K

Top employee countries

United States10.9K

India7.2K

Switzerland6K

France1.5K

Spain1.4K

Czechia1.3K

China1.3K

Active job openings

Selected open roles that reveal current hiring demand.

County Executive

Open role

3949105726

IT Strategic Business Partner US&I (Salesforce)

Open role

4095702924

PRODUCT MANAGER (H/F) en alternance

Open role

4229469538

Therapeutic Data Strategy Director

Open role

4257658803

ED, Evidence Generation TA Head - Oncology

Open role

4258155701

ED, Evidence Generation TA Head - Oncology

Open role

4258157491

Patient Safety Group Manager

Open role

4293935219

Sales Executive

Open role

4313838907

Showing 8 of 18 available records.

Where employees came from

Common previous employers visible in employee profile movement.

Pfizer

4.2K employee movements

Internal profile link

GSK

3.6K employee movements

Internal profile link

Sandoz

3.3K employee movements

Internal profile link

Sanofi

3.1K employee movements

Internal profile link

Roche

2.6K employee movements

Internal profile link

AstraZeneca

2.5K employee movements

Internal profile link

Alcon

1.9K employee movements

Internal profile link

Bristol Myers Squibb

1.6K employee movements

Internal profile link

Showing 8 of 9 available records.

Where employees go next

Common next employers visible in employee profile movement.

GSK

5.7K employee movements

Internal profile link

Sandoz

3.1K employee movements

Internal profile link

Roche

3K employee movements

Internal profile link

Sanofi

3K employee movements

Internal profile link

Pfizer

2.7K employee movements

Internal profile link

AstraZeneca

2.7K employee movements

Internal profile link

Bristol Myers Squibb

1.7K employee movements

Internal profile link

Bayer

1.6K employee movements

Internal profile link

Showing 8 of 10 available records.

Product and reputation

Product readiness, customer proof, and employee sentiment

Product availability, public reviews, and employee sentiment help visitors understand whether the company is mature, documented, reviewable, and operationally healthy.

Product availability Q&A

Buyer-facing product availability signals in question-and-answer format.

Is pricing information available?

Yes. The source snapshot lists pricing information for this company.

Source availability signal

Is a free trial listed?

No. The source snapshot does not list a free trial for this company.

Source availability signal

Can buyers request a demo?

No. The source snapshot does not list a demo motion for this company.

Source availability signal

Is the product downloadable?

Yes. The source snapshot lists downloadable software for this company.

Source availability signal

Are mobile apps listed?

No. The source snapshot does not list mobile apps for this company.

Source availability signal

Is public documentation listed?

No. The source snapshot does not list public documentation for this company.

Source availability signal

Are online reviews listed?

No. The source snapshot does not list online reviews for this company.

Source availability signal

Company graph

Technology, leadership, competitors, funding, and corporate activity

These data points help sales, partnerships, analysts, and researchers understand how the company operates, who surrounds it, and where it may be moving next.

Verified technologies

Detected tools and systems verified in the source dataset.

Microsoft 365

Verified technology

Last verified 2026-05-04 | First seen 2025-08-17

Icontrol

Verified technology

Last verified 2026-05-04 | First seen 2025-08-17

Brocade

Verified technology

Last verified 2026-05-04 | First seen 2024-05-20

Aos

Verified technology

Last verified 2026-05-04 | First seen 2024-04-04

Sap Ariba

Verified technology

Last verified 2026-05-04 | First seen 2024-05-20

Samsung

Verified technology

Last verified 2026-05-04 | First seen 2025-08-17

Pearson Vue

Verified technology

Last verified 2026-05-04 | First seen 2025-02-20

Msi

Verified technology

Last verified 2026-05-04 | First seen 2025-08-17

Showing 8 of 24 available records.

Market alternatives and competitors

Comparable companies surfaced by the source dataset.

Bayer

Comparable company

Market alternative

Johnson & Johnson

Comparable company

Market alternative

Gilead Sciences

Comparable company

Market alternative

Sanofi

Comparable company

Market alternative

Merck Group

Comparable company

Market alternative

Immunomedics

Comparable company

Market alternative

Pfizer

Comparable company

Market alternative

Astrazeneca

Comparable company

Market alternative

Showing 8 of 12 available records.

Leadership and senior operators

Senior employees and operators visible in the source dataset.

Torsten Seppmann

International Medical Affairs Director - Renal (rotation)

Marina Basin

Associate Director Market Research

Anna Fantozzi

Associate Director, RA CMC

Zaoui Naziha

Market Access And Public Affairs MTA Head

Brian Donahue

Associate Director, Medical Science Liaison (Cardiovascular)

Rui Sun

Medical Director

Rajesh Bhayankaram

Associate Director

Arjun Sawhney

Director, Integrated Field Insights & Analytics

Showing 8 of 12 available records.

Recent executive arrivals

Recent leadership and senior employee arrival signals.

Lovleen Arya

Associate Director, Medical Information & Engagement

Jan 2026

Fabienne Porchet

Director, Product Owner, Content Lifecycle

Jan 2026

Luiz Rodrigues

Recruitment Experience Partner US - Research and Development

Apr 2026

Matthew Brierley

Director, Statistical Programming

Jan 2026

Chaitanya chinta

Workday Product Owner

Dec 2025

Tobias Beyer

Strategic Marketing Lead Oncology

Jan 2026

Sara Valente

Global Director Patient Engagement Oncology

Feb 2026

Lovemore Gakava

Associate Director

Jan 2026

Recent executive departures

Recent leadership and senior employee departure signals.

Luiz Rodrigues

Talent Acquisition Business Partner

Apr 2026

Tobias Beyer

Strategic Marketing Lead Breast Cancer

Dec 2025

Alex Thiele Orejas

Associate Director Data Science

Jan 2026

Agathi Balampani

Supply Chain Europe Adopt Lead

Apr 2026

Timothy Witkowski

Global Head, Chemistry Patents

Apr 2026

Balmiki Ghosh

Associate Director Project Management

Mar 2026

Stuart Duneclift

a.i. Country Patient Safety Head UK, Deputy UK QPPV

Dec 2025

Florencia Anfuso

Access Business Partner

Feb 2026

Company locations

Known company locations and office addresses.

Primary location

Novartis Campus; Basel, Baselstadt 4002, CH

Office location

Lima, PE

Office location

Baku, AZ

Office location

Caracas, VE

Office location

Moscow, RU

Office location

Dakar, SN

Office location

Brussels, BE

Office location

Doha, QA

Recent company updates

Recent company update signals from the source dataset.

At only 12 weeks old, Wonder was admitted to a hospital in Ghana with life-threatening malaria. Until recentl…

450 reactions; 24 comments

2026-04-24 | At only 12 weeks old, Wonder was admitted to a hospital in Ghana with life-threatening malaria. Until recently, there were no medicines designed for babies his weight. Wonder was one of the first babies treated with a…

Early conversations can positively shape an entire chronic myeloid leukemia (CML) journey. For Victoria, spe…

170 reactions; 5 comments

2026-04-21 | Early conversations can positively shape an entire chronic myeloid leukemia (CML) journey. For Victoria, speaking openly with her doctor, Dr. Tim Hughes, made all the difference. Together, they share how creating space…

This Sjögren’s Awareness Month, we’re thrilled TV personality and Sjögren's advocate Carrie Ann Inaba is lend…

503 reactions; 6 comments

2026-04-16 | This Sjögren’s Awareness Month, we’re thrilled TV personality and Sjögren's advocate Carrie Ann Inaba is lending her voice to our new campaign, SJÖUT for Sjögren’s. Sjögren’s disease is a serious, systemic autoimmune d…

Sustainability and social impact underpin how Novartis drives long‑term performance, strengthening resilience…

252 reactions; 13 comments

2026-04-15 | Sustainability and social impact underpin how Novartis drives long‑term performance, strengthening resilience, fuelling innovation and supporting healthcare systems for the future. We also know that progress happens fas…

For Maria, the fight against Chagas disease is personal. Her mother is one of the millions of people in L…

246 reactions; 4 comments

2026-04-14 | For Maria, the fight against Chagas disease is personal. Her mother is one of the millions of people in Latin America who have been impacted by this life-changing parasitic infection. With Novartis, she is helping t…

The epidemic of chronic disease goes beyond breakthrough medicines, and so do we. From the U.S. to emerging…

488 reactions; 28 comments

2026-04-09 | The epidemic of chronic disease goes beyond breakthrough medicines, and so do we. From the U.S. to emerging economies, Novartis is expanding efforts to bring better care for cancer and heart disease to communities beyo…

Industry classification codes

SIC, NAICS, industry, and keyword classification signals.

Industry

Pharmaceutical Manufacturing

industry

Categories and keywords

Categories And Keywords

Public market signal

Novartis stock snapshot

TradingView market widget for NYSE:NVS.

NYSE:NVS

Novartis FAQs

Company profile

Want verified contact data for Novartis?

Datakart.ai gives you verified email addresses, direct dials, and buying intent signals for key decision-makers at Novartis and 1,700+ other companies.

Start your free trial Directory